Philip Morris Closes In On Vectura As £1.1bn Offer Passes Threshold
Takeover Steeped In Controversy, With Objections Raised By Healthcare Charities
Philip Morris once again pledged to up R&D in Vectura after its £1.1bn takeover offer for the UK-based inhalation specialist became unconditional, following the tobacco giant’s acrimonious face-off with private equity Carlyle earlier this year.
You may also be interested in...
Viyash Life Sciences said it intended to seek further investment opportunities to build scale after establishing an integrated generic pharmaceutical platform in India in partnership with the private equity giant Carlyle.
Looking back over a busy third quarter in 2021, Generics Bulletin executive editor David Wallace picks out highlights from July to September that include major legal and regulatory developments, multiple firsts in the biosimilars arena, significant M&A activity and our annual ranking of the off-patent sector’s top 50 companies.
Weeks after partner Hikma launched its generic version of GSK’s Advair, Wiltshire-based Vectura has agreed a takeover offer by private equity Carlyle, which aims to build a market leading inhalation specialist CDMO.